Subscribe
scientist-istock-505918900-1
gevende / iStockphoto.com
11 December 2018Biotechnology

AstraZeneca to launch CRISPR-based cancer research centre

Pharmaceutical company AstraZeneca and charity Cancer Research UK have announced that they will launch a centre to accelerate the discovery of new cancer treatments.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
CRISPR babies still too risky, warns new report
10 September 2020   Human embryos whose genomes have been edited should not be used to create a pregnancy until it is certain that changes can be made without introducing undesired changes, according to a new report by an influential panel.
Big Pharma
AstraZeneca and Daiichi Sankyo to develop new cancer treatment
2 April 2019   Biopharmaceutical company AstraZeneca has entered into an agreement with Japanese pharmaceutical company Daiichi Sankyo to develop and commercialise trastuzumab deruxtecan, a potential new medicine for cancer treatment.
Biotechnology
Cancer Research UK forms immunotherapy alliance
28 March 2019   Cancer Research UK has formed a multimillion-pound drug discovery alliance with fellow charity LifeArc and Japanese company Ono Pharmaceutical.


Editor's picks

Life sciences leaders recognised at LSPN Awards USA 2025
Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025

Editor's picks

Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025
Americas
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
6 May 2025
Americas
Why US patent reform is ‘essential’ for US economic prosperity and security
29 April 2025
Europe
Meril v Edwards: Harmonisation of obviousness at the UPC and the EPO
24 April 2025
Americas
WIPR Diversity & Inclusion reveals Top 100 People in IP for 2025
24 April 2025
Big Pharma
AstraZeneca unit faces class-action suit over alleged Soliris monopoly
17 April 2025

More on this story

Americas
CRISPR babies still too risky, warns new report
10 September 2020   Human embryos whose genomes have been edited should not be used to create a pregnancy until it is certain that changes can be made without introducing undesired changes, according to a new report by an influential panel.
Big Pharma
AstraZeneca and Daiichi Sankyo to develop new cancer treatment
2 April 2019   Biopharmaceutical company AstraZeneca has entered into an agreement with Japanese pharmaceutical company Daiichi Sankyo to develop and commercialise trastuzumab deruxtecan, a potential new medicine for cancer treatment.
Biotechnology
Cancer Research UK forms immunotherapy alliance
28 March 2019   Cancer Research UK has formed a multimillion-pound drug discovery alliance with fellow charity LifeArc and Japanese company Ono Pharmaceutical.

More on this story

Americas
CRISPR babies still too risky, warns new report
10 September 2020   Human embryos whose genomes have been edited should not be used to create a pregnancy until it is certain that changes can be made without introducing undesired changes, according to a new report by an influential panel.
Big Pharma
AstraZeneca and Daiichi Sankyo to develop new cancer treatment
2 April 2019   Biopharmaceutical company AstraZeneca has entered into an agreement with Japanese pharmaceutical company Daiichi Sankyo to develop and commercialise trastuzumab deruxtecan, a potential new medicine for cancer treatment.
Biotechnology
Cancer Research UK forms immunotherapy alliance
28 March 2019   Cancer Research UK has formed a multimillion-pound drug discovery alliance with fellow charity LifeArc and Japanese company Ono Pharmaceutical.

More features

Life sciences leaders recognised at LSPN Awards USA 2025
UK-India trade deal is ‘a missed opportunity for UK pharma’, says industry body
LSPN: Counsel grapple with AI’s impact on training and critical thinking
'Nothing can stand in the way of our work': Ukraine resumes IP system
LSPN: Trump's policy storm causing chaos and confusion
Taylor Wessing expands in Europe with Paris team
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
ResMed voids sleep apnoea tech patent at PTAB